Is cancer gene therapy an empty suit?

Summary Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have...

Full description

Saved in:
Bibliographic Details
Published inThe lancet oncology Vol. 14; no. 11; pp. e447 - e456
Main Authors Brenner, Malcolm K, Prof Dr, Gottschalk, Stephen, Prof, Leen, Ann M, PhD, Vera, Juan F, MD
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.10.2013
Elsevier Limited
Subjects
Animals
Biodistribution
Biological products
Cancer therapies
Disease
Gene therapy
Genes, Tumor Suppressor
Genetic disorders
Genetic engineering
Genetic Therapy
Hematology, Oncology and Palliative Medicine
Hemophilia
Humans
Immune system
Immunotherapy
Neoplasms - genetics
Neoplasms - therapy
Pharmaceutical industry
Success
Tumors
Online AccessGet full text

Cover

More Information
Summary:Summary Gene therapy as a treatment for cancer is regarded as high in promise, but low in delivery, a deficiency that has become more obvious with ever-increasing reports of the successful correction of monogenic disorders by this approach. We review the commercial and scientific obstacles that have led to these delays and describe how they are progressively being overcome. Recent and striking successes and correspondingly increased commercial involvement suggest that gene transfer could finally become a powerful method for development of safe and effective cancer therapeutic drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-2
ObjectType-Feature-2
ISSN:1470-2045
1474-5488
DOI:10.1016/S1470-2045(13)70173-6